NCT05924074Recruiting
Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
Source: ClinicalTrials.gov · Last updated 19 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Myelodysplastic syndromes (MDS) are clonal diseases of hematopoietic stem cells (HSC) characterized by dysplastic and inefficient hematopoiesis related to excessive progenitor cell death. Ferroptosis is a recently described cell death mechanism and we think that it could be a major player in the pathophysiology of MDS, involved in the cell death that characterizes these diseases and contributing to cytopenias. The study aims to demonstrate that there is a significant activation of this phenomenon in MDS patients compared to a population of subjects without MDS.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 7 Jun 2023
- Start date
- 21 Feb 2025
- Primary completion date
- Feb 2027
- Lead sponsor
- University Hospital, Bordeaux
- Diseases
- Myelodysplastic syndromes
- NCT number
- NCT05924074
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 21 Feb 2025 to the primary completion date, Feb 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient transfused with red blood cells within 120 days prior to collection
- Patients treated with haematopoietic growth factors (EPO, TPO, G-CSF) within 30 days prior to collection
- Subject who is in an exclusion period after another study or who has participated in another interventional drug study within 30 days prior to entry into the protocol
Other illness
- Patients with conditions that affect systemic iron metabolism: hemochromatosis, Gaucher disease, ferroportin disease, porphyria cutanea tarda
Other
- For all
- Person under a legal protection measure (legal protection, guardianship or curatorship)
- Person deprived of liberty by judicial or administrative decision
- Person who is unable to give consent
Who the study is looking for
- For all :
- Patients of legal age (age ≥ 18 years)
- Subjects affiliated to or benefiting from a social security scheme
- Free, written and informed consent signed by the participant and the investigator
- For MDS patients :
- Sampling at diagnosis for MDS patients (WHO 2016 criteria)
- Presence of ring sideroblasts on bone marrow smear
- For MGUS patients :
- \- Sampling as part of the exploration of monoclonal gammopathy of undetermined significance (MGUS) for controls (WHO 2016 criteria).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Bordeaux - service de médecine interne Coordinator of this site? Confirm its status | Pessac | France | Not yet recruiting |
| CHU de Bordeaux, Laboratoire d'Hématologie Coordinator of this site? Confirm its status | Pessac | France | Not yet recruiting |
| CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire Coordinator of this site? Confirm its status | Pessac | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.